Project Grant R43HL170906
Award Date
9/1/23
Completion Date
8/31/24
Dollars Obligated
$294K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Sigt LLC (TDS1HMV3LM26)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. The funding supports the development of a novel, smartwatch-enabled technology that allows patients with low-risk atrial fibrillation to safely initiate antiarrhythmic medications at home. The technology analyzes post-drug ECG data taken by patients using a machine learning algorithm and provides this information to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $323,230 to Sirona Medical Technologies, Inc. to develop a customizable, multi-channel, dual energy source generator for their cardiac ablation catheter system. The goal is to create hardware to interface Sirona's catheter designs with radiofrequency (RF) and pulsed field (PF) energy generator platforms, and establish safe and...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $298,368 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Link Medical LLC, a for-profit limited liability company located in Chelsea, Michigan. The grant supports the development of a novel catheter-based technology to treat mitral valve regurgitation, a common cardiovascular condition. The project aims to optimize the device design and procedure through bench testing, followed by conducting in vivo...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $294,023 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Heartlung Corporation to develop the AUTOCHAMBER AI tool. AUTOCHAMBER is designed to opportunistically screen existing chest CT scans for early detection of enlarged cardiac chambers and left ventricular hypertrophy, which can indicate risk of atrial fibrillation, stroke, and heart failure. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,035,951.00 to Safebeat RX Inc. to develop a novel, automated mobile heart rhythm analysis technology. The goal is to allow patients with atrial fibrillation (AF), the most common heart rhythm disorder affecting over 38 million people worldwide, to safely start taking antiarrhythmic drugs at home. This would improve...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $251,156 to City Labs, Inc. to develop a betavoltaic power source for leadless cardiac pacemakers (LCPs). The grant aims to create a compact, long-lasting power solution for LCPs that can significantly reduce their size and extend their lifespan to 20 years, enabling new applications and improving patient outcomes. The project will...